Secondary Cancers

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

In this video, Tycel Phillips, MD, discusses conditions common in patients with DLBCL.

CHICAGO — Survivors of high-risk neuroblastoma face a substantial burden of late toxicity, according to study results presented at ASCO Annual Meeting.

In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.

Although many cancer survivors go on to live healthy, cancer-free lives, the prospect of facing cancer again is an ongoing concern.